25x-NBOMe is the general form of the NBOMe series of psychedelic phenethylamines. The series had nearly no history of human use before 2010 when some of the first compounds became available for purchase from online research chemical vendors.
While members of this series are often misrepresented as LSD, a fundamental difference between them is that 25x-NBOMe is only active when taken through a sublingual or insufflated route. This means that to get the full effects, 25x-NBOMe blotter paper must be lightly chewed on for 20+ minutes and never immediately swallowed.
25x-NBOMe blotters cause numbness of the tongue and have a distinct taste that is often described as "strongly bitter", "metallic", or "chemical like". This is unlike LSD blotters, which will not cause numbness of the tongue and may be tasteless or have a slight flavor depending on the amount of ink on the blotter and the composition of the blotter paper.
Although these differences can be helpful in identifying an unwanted compound on a blotter, it is recommended that more reliable methods of identification be used, such as the use of testing reagents like the Ehrlich reagent.
Insufflation of these substances are highly discouraged due to numerous reports of people suffering dangerous and often fatal overdoses that have surfaced over the years.
In a comparison of 25x-NBOMe and 2C-x chemicals, each 25x-NBOMe molecule is a serotonergic N-benzyl derivative of the corresponding 2C-x molecule. This change in structure results in an increase in potency. It differs from the related 2C-x structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group. The addition of this BOMe group also causes most of the compounds to have relatively the same duration, regardless of how long the 2C-x counterpart lasts.
List of 25x-NBOMe compounds
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
Tolerance and addiction potential
Members of the 25x-NBOMe series are not habit-forming and the desire to use them can actually decrease with use. They are thought to be most often self-regulating.
Tolerance to the effects of any member of the 25x-NBOMe series is built almost immediately after ingestion. After that, it takes about 1 week for the tolerance to be reduced to half and 2 weeks to be back to baseline (in the absence of further consumption). Members of the 25x-NBOMe series present cross-tolerance with all psychedelics, meaning that after the consumption of any member of the 25x-NBOMe series all psychedelics will have a reduced effect.
Although many psychoactive substances are safe to use on their own, they can become dangerous or even life-threatening when taken with other substances. The list below contains some potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses but still increase the possibility of injury of death. Independent research should always be conducted to ensure that a combination of two or more substances is safe before consumption.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
- Lithium - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its glutaminergic and GABAergic effects.
Serotonin syndrome risk
- MAOIs such as syrian rue, banisteriopsis caapi, 2C-T-2, 2C-T-7, αMT, and some antidepressants
- Serotonin releasers such as MDMA, 4-FA, methylone and αMT
- Selective serotonin re-uptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as tramadol and DXM
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- United States: In the US, some of the 25x-NBOMe chemicals are listed as Schedule I substances and others may be considered analogues under the Federal Analogue Act.
- United Kingdom - The majority of synthesised 25x-NBOMe substances are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause. Any compounds not covered by the clause are illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Bräuner-Osborne, H., & Kristensen, J. L. (2014). Synthesis and structure–activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chemical Neuroscience, 5(3), 243-249. https://doi.org/10.1021/cn400216u
- Heim, Ralf (2004). "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur". Freie Universität Berlin. Retrieved 27 June 2015.
- Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMC 3963123 Freely accessible. PMID 24397362. https://doi.org/10.1021/cn400216u
- Ettrup, A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–693. PMID 21174090. https://doi.org/10.1007/s00259-010-1686-8
- 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
- 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
- Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441. https://doi.org/10.1093/bja/aei210
- United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted